PathWays Case Study: March 1

The following case was highlighted at the 2015 American Society of Hematology Conference in Orlando, Florida.

Your Score:  

Your Ranking:  

Min Shi, M.D., Ph.D.

Min Shi, M.D., Ph.D.
Consultant, Division of Hematopathology
Mayo Clinic
Assistant Professor of Laboratory Medicine and Pathology,
Mayo Clinic College of Medicine

apriljosselyn

April Josselyn

April Josselyn is a Marketing Associate at Mayo Medical Laboratories. She is the editor of Mayo Clinic PathWays and supports corporate communications strategies and internal communications. She has worked at Mayo Clinic since 2012. Outside of work, April enjoys the outdoors and being "hockey mom" for her two sports-crazed boys.

Responses

Real indication of allogeneic sct in hemooncology is still debate

Could you explain the significance of the FLT3-ITD mutation — for those of us who aren’t up to date on the latest in hematopathology?

Hi Lynn, FLT3-ITD mutation is a frequent molecular abnormality in AML patients. Many studies have shown this mutation carries unfavorable prognosis, resulting in shorter remission durations and poor survival outcomes. – Dr. Shi

Comments are closed.